CTOs on the Move


 
Emocha uses video technology and human engagement to empower patients to take every dose of medication as prescribed. emocha facilitates a daily touchpoint for patients in order to expand access to treatment, extend the reach of existing care teams, and retain patients in care. emocha`s turnkey, enterprise adherence solution operates through dose-by-dose observation and clinical assessment of potential administration problems, including technique and side effects. Coupled with daily engagement, support, and incentives, emocha is the first holistic solution to medication non-adherence.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.emocha.com
  • 916 North Charles Street 2120, 12nd Floor - Suite 200
    Baltimore, MD USA 21221
  • Phone: 410.864.8587

Executives

Name Title Contact Details
Ramon Castro
Chief Technology Officer Profile
Gorkem Sevinc
Chief Technology Officer and Co-Founder Profile

Similar Companies

Fonix Speech

Fonix Speech, Inc. is a Lindon, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

United BioSource Corporation

United BioSource Corporation is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

ATS Health Services

ATS Health Services is a Jacksonville, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MedComm Solutions

MedComm Solutions is a Morrisville, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Orbus Therapeutics

Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company’s product candidate in development is eflornithine in an oral solution. Eflornithine is a novel cytostatic agent, which Orbus Therapeutics is developing for the treatment of patients with anaplastic glioma (AG), or Grade 3 glioma, a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in various types of cancer. Orbus Therapeutics intends to develop and commercialize eflornithine in North America.